58579-54-7

Usage

Uses

Used in Pharmaceutical Industry:
1-broMo-2-(broMoMethyl)-3-nitrobenzene is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its bromine and nitro groups can be further functionalized to create a wide range of drug candidates with potential therapeutic applications.
Used in Chemical Synthesis:
1-broMo-2-(broMoMethyl)-3-nitrobenzene is used as a reagent in the synthesis of various organic compounds, including 3and 4-substituted indoles. Its unique structure allows for selective functionalization and reaction with other molecules, making it a valuable building block in organic chemistry.
Used in Material Science:
1-broMo-2-(broMoMethyl)-3-nitrobenzene is used as a component in the preparation of acid photogenerators for lithographic resist applications. Its ability to undergo specific chemical reactions makes it a useful starting material for the development of advanced materials with potential applications in microelectronics and other high-tech industries.

Upstream product

• 55289-35-5 2-bromo-6-nitrotoluene 
• 603-83-8 3-nitro-o-tolylamine 

Downstream Products

• 109019-72-9 1-(2-Bromo-6-nitrobenzyl)pyridinium bromide 
• 90481-67-7 (2-Bromo-6-nitro-benzyl)-triphenyl-phosphonium; bromide 
• 109513-33-9 C₁₅H₁₄BrN₃O₃ 
• 887906-16-3 2-(2-bromo-6-nitro-benzyl)-malonic acid diethyl ester 
• 109513-33-9 2-Bromo-6-nitrobenzylidene(p-dimethylaminophenyl)amine N-Oxide 
• 52488-36-5 4-bromo-1H-indole 
• 90481-72-4 4-bromo-1-[(4-methylphenyl)sulfonyl]-1H-indole 
• 90481-69-9 3-bromo-2-ethenylaniline 
• 90481-68-8 1-bromo-2-ethenyl-3-nitrobenzene 
• 90481-70-2 3-bromo-2-ethenylacetanilide 
• 90481-71-3 N-tosyl-3-bromo-2-ethenylaniline 
• 90481-78-0 3,4-dibromo-1-tosylindole 
• 90481-75-7 4-(2-phenylethen-1-yl)-1-tosylindole 
• 90481-73-5 (E)-methyl 3-(1-tosyl-1H-indol-4-yl)acrylate 

Relevant academic research and scientific papers

Novel Bruton's tyrosine kinase inhibitor as well as preparation method and application thereof

The invention relates to a reversible novel Bruton's tyrosine kinase inhibitor which comprises a compound of a formula (I) as shown in the specification, and a stereisomer, a aquo-complex, a solvent compound, a pharmaceutically acceptable salt, an eutectic crystal or a predrug of the compound. The invention further relates to a preparation method of the compound and a method and the application ofthe novel compound in inhibiting BTK (Bruton's Tyrosine Kinase) kinase activity and mutant BTK kinase activity.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

SUBSTITUTED 1H-PYRROLOPYRIDINONE DERIVATIVES AS KINASE INHIBITORS

The present invention provides novel substituted 1H-Pyrrolopyridinone derivatives of formula (1) as protein kinase inhibitors, in which R1, R2, R3, R4, R5, R6 and 'p' have the meanings given in the specification, and pharmaceutically acceptable salts thereof that are useful in the treatment and prevention in diseases or disorder, in particular their use in diseases or disorder where there is an advantage in inhibiting kinase enzyme, more particularly BTK enzyme. The present invention also provides methods for synthesizing and administering the kinase inhibitor compounds. The present invention also provides pharmaceutical formulations comprising at least one of the kinase inhibitor compounds together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

FUSED QUINAZOLINE DERIVATIVES AND USES THEREOF

Fused quinazoline derivatives and uses thereof as protein tyrosine kinase inhibitors and aurora kinase inhibitors are disclosed. Said protein tyrosine kinase inhibitors and aurora kinase inhibitors can be used in treating cancers, leukaemia and the diseases relevant to differentiation and proliferation. Said protein tyrosine kinase and aurora kinase dual inhibitors are the compounds represented by the following general formula or salts thereof.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

POLYCYCLIC QUINAZOLINES, PREPARATION THEREOF, AND USE THEREOF

At least one active pharmaceutical ingredient is chosen from polycyclic quinazolines of formula V, pharmaceutically acceptable salts thereof, and hydrates of the pharmaceutically acceptable salts. The active pharmaceutical ingredients disclosed may be inhibitors of protein tyrosine kinase inhibitors and/or aurora kinase. The active pharmaceutical ingredients can be used for treating cancers susceptible to treatment with protein tyrosine kinase inhibitors and/or aurora kinase inhibitors.

Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties

We have synthesized and evaluated a new series of acyclic P4-benzoxaborole-based HCV NS3 protease inhibitors. Structure-activity relationships were investigated, leading to the identification of compounds 5g and 17 with low nanomolar potency in the enzymatic and cell-based replicon assay. The linker-truncated compound 5j was found to exhibit improved absorption and oral bioavailability in rats, suggesting that further reduction of molecular weight and polar surface area could result in improved drug-like properties of this novel series.

Structure-activity relationships of 3,4-dihydro-1H-quinazolin-2-one derivatives as potential CDK5 inhibitors

Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase that plays a critical role in the early development of the nervous system. Deregulation of CDK5 is believed to contribute to the abnormal phosphorylation of various cellular substrates associated with neurodegenerative disorders such as Alzheimer's disease, amyotrophic lateral sclerosis, and ischemic stroke. Acyclic urea 3 was identified as a potent CDK5 inhibitor and co-crystallographic data of urea 3/CDK2 enzyme were used to design a novel series of 3,4-dihydroquinazolin-2(1H)-ones as CDK5 inhibitors. In this investigation we present our synthetic studies toward this series of compounds and discuss their biological relevance as CDK5 inhibitors.

Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase Cε and η

Conventional (α, βI, βII, γ) and novel (δ, ε, η, θ) protein kinase C (PKC) isozymes are main targets of tumor promoters, such as phorbol esters and indolactam-V (ILV). We have recently found that 1-hexyl derivatives of indolinelactam-V (2, 3), in which th

1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATME

The invention relates to substituted quinazolinone compunds of formula (I) or a pharmaceutically acceptable salt thereof, wherein Y is C or S; m is 1 when Y is C and m is 2 when Y is S; n is 1 or 2; p is from 0 to 3; q is from 1 to 3; Z is -(CRa/sup